ALS Clinical Trials in Houston

Showing 21-32 of 32 trials

Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation

NCT02794857

This study evaluates NP001 in patients with amyotrophic lateral sclerosis (ALS) and evidence of systemic inflammation. Half of participants will receive NP001 and the other half will receive placebo.

Amyotrophic Lateral Sclerosis

Neuraltus Pharmaceuticals, Inc.138 participantsStarted Aug 2016

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • Los Angeles, California, United States +19 more locations

UNKNOWNPHASE1< 1 mile

T-Regulatory Cells in Amyotrophic Lateral Sclerosis

NCT03241784

This is an open-label pilot study to determine the safety and tolerability of infusions of autologous CD4+ CD25+ regulatory T cells with concomitant subcutaneous IL-2 injections in 4 subjects with ALS.

ALS (Amyotrophic Lateral Sclerosis)

Stanley H. Appel, MD4 participantsStarted May 2016

Houston, Texas, United States

PreviousPage 2 of 2

Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation

T-Regulatory Cells in Amyotrophic Lateral Sclerosis

ALS Trials in Other Cities

Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Oral Baclofen Pharmacokinetics and Pharmacodynamics in Children With Spasticity

Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS)

Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS

Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls

A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS

A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS

Creatine for the Treatment of Amyotrophic Lateral Sclerosis

Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis

Other Conditions in Houston